The emerging predictive and prognostic role of aggressive-variant-associated tumor suppressor genes across prostate cancer stages
Additional information
Authors
Pedrani M.,
Barizzi J.,
Salfi G.,
Nepote A.,
Testi I.,
Merler S.,
Castelo-Branco L.,
Pereira Mestre R.,
Turco F.,
Tortola L.,
Theurillat J. P.,
Gillessen Sommer S.,
Vogl U.
Type
Journal Article
Year
2025
Language
English
Abstract
Aggressive variant prostate cancer (AVPC) is characterized by a molecular signature involving combined defects in TP53, RB1, and/or PTEN (AVPC-TSGs), identifiable through immunohistochemistry or genomic analysis. The reported prevalence of AVPC-TSG alterations varies widely, reflecting differences in assay sensitivity, treatment pressure, and disease stage evolution. Although robust clinical evidence is still emerging, the study of AVPC-TSG alterations in prostate cancer (PCa) is promising. Alterations in TP53, RB1, and PTEN, as well as the combined loss of AVPC-TSGs, may have significant implications for prognosis and treatment. These biomarkers might help predict responses to various therapies, including hormonal treatments, cytotoxic agents, radiotherapy, and targeted therapies. Understanding the impact of these molecular alterations in patients with PCa is crucial for personalized management. In this review, we provide a comprehensive overview of the emerging prognostic and predictive roles of AVPC-TSG alterations across PCa stages. Moreover, we discuss the implications of different methods used for detecting AVPC-TSG alterations and summarize factors influencing their prevalence. As our comprehension of the genomic landscape of PCa disease deepens, incorporating genomic profiling into clinical decision making will become increasingly important for improving patient outcomes.
Keywords
Aggressive variant prostate cancer (AVPC), Tumor suppressor genes (TSGs), TP53, RB1, PTEN, Prostate cancer, Prognosis, Predictive, Targeting
Journal
International journal of molecular sciences
Volume
26
Number ( Month )
1
Pages (or article number)
318
Diffusion
License
CC BY
Visibility
Public
Status open access
Gold
